Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

9.930 -0.185 (-1.83%)

Streaming Delayed Price Updated: 1:42 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

What 4 Analyst Ratings Have To Say About Ocular Therapeutix ↗

March 18, 2025

Via Benzinga

Why Ocular Therapeutix Was Bumping Higher This Week ↗

March 14, 2025

Via The Motley Fool

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside ↗

March 11, 2025

Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales.

Via Benzinga

This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

March 11, 2025

Via Benzinga

Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback ↗

March 03, 2025

The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.

Via Stocktwits

Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts ↗

December 03, 2024

Via Benzinga

A Peek at Ocular Therapeutix's Future Earnings ↗

November 13, 2024

Via Benzinga

Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock ↗

August 01, 2024

Via Benzinga

Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings) ↗

June 14, 2024

Via Benzinga

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 13, 2025

Via Benzinga

3 Biotech Stocks to Sell in August Before They Crash & Burn ↗

August 06, 2024

Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.

Via InvestorPlace

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts ↗

April 16, 2024

Via Benzinga

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 20, 2024

Via Benzinga

KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday ↗

June 20, 2024

Via Benzinga

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

June 20, 2024

Via Benzinga

Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday ↗

June 20, 2024

Via Benzinga

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 14, 2024

Via Benzinga

Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday ↗

June 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 28, 2024

Via Benzinga

OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

OCUL stock results show that Ocular Therapeutix missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 06, 2024

Via Benzinga

BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

May 06, 2024

Via Benzinga

2 Small-Cap Growth Stocks With Room To Run ↗

April 24, 2024

These two small-cap growth stocks could be ready to run.

Via The Motley Fool

Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

April 19, 2024

Via Benzinga

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder ↗

April 18, 2024

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data...

Via Benzinga

Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 18, 2024

Via Benzinga

The 3 Best Biotech Stocks to Buy Now: Q2 Edition ↗

April 16, 2024

Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.

Via InvestorPlace

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗

April 15, 2024

With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.